Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
547 results:
1. [Genetic drivers for inflammatory protein markers in colorectal cancer: a Mendelian randomization approach to clinical prognosis study].
Li H; Li G; Zhang X; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Jul; 44(7):1361-1369. PubMed ID: 39051082
[TBL] [Abstract] [Full Text] [Related]
2. Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis.
Yu H; Liu Q; Wu K; Tang S
Clin Exp Med; 2024 Jul; 24(1):143. PubMed ID: 38960935
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic and therapeutic insights into colorectal carcinoma through immunogenic cell death gene profiling.
Yu J; Gong Y; Xu Z; Chen L; Li S; Cui Y
PeerJ; 2024; 12():e17629. PubMed ID: 38938617
[TBL] [Abstract] [Full Text] [Related]
4. Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-pd-l1 therapy.
Yang Z; Chu B; Tu Y; Li L; Chen D; Huang S; Huang W; Fan W; Li Q; Zhang C; Yuan Z; Huang J; Leung EL; Jiang Y
Pharmacol Res; 2024 Aug; 206():107271. PubMed ID: 38906202
[TBL] [Abstract] [Full Text] [Related]
5. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.
Berland L; Gabr Z; Chang M; Ilié M; Hofman V; Rignol G; Ghiringhelli F; Mograbi B; Rashidian M; Hofman P
Front Immunol; 2024; 15():1384121. PubMed ID: 38903504
[TBL] [Abstract] [Full Text] [Related]
6. Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing pd-l1 expression and optimizing the tumor microenvironment.
Jia M; Yuan Z; Yu H; Feng S; Tan X; Long Z; Duan Y; Zhu W; Yan P
Biomed Pharmacother; 2024 Jul; 176():116883. PubMed ID: 38876047
[TBL] [Abstract] [Full Text] [Related]
7. The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
Yang L; Cui X; Wu F; Chi Z; Xiao L; Wang X; Liang Z; Li X; Yu Q; Lin X; Gao C
Front Immunol; 2024; 15():1392499. PubMed ID: 38846948
[TBL] [Abstract] [Full Text] [Related]
8. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
Tsukada Y; Bando H; Inamori K; Wakabayashi M; Togashi Y; Koyama S; Kotani D; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Sato A; Nishikawa H; Ito M; Yoshino T
Br J Cancer; 2024 Jul; 131(2):283-289. PubMed ID: 38834744
[TBL] [Abstract] [Full Text] [Related]
9. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H
Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657
[TBL] [Abstract] [Full Text] [Related]
10. Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan.
Takahashi R; Osumi H; Wakatsuki T; Yamamoto N; Taguchi S; Nakayama I; Ooki A; Ogura M; Takahari D; Chin K; Yamaguchi K; Shinozaki E
Int J Clin Oncol; 2024 Aug; 29(8):1161-1172. PubMed ID: 38819609
[TBL] [Abstract] [Full Text] [Related]
11. PD-1/pd-l1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
[TBL] [Abstract] [Full Text] [Related]
12. The therapeutic impact of programmed death - 1 in the treatment of colorectal cancer.
Sangani PS; Yazdani S; Khalili-Tanha G; Ghorbani E; Al-Hayawi IS; Fiuji H; Khazaei M; Hassanian SM; Kiani M; Ghayour-Mobarhan M; Ferns GA; Nazari E; Avan A
Pathol Res Pract; 2024 Jul; 259():155345. PubMed ID: 38805760
[TBL] [Abstract] [Full Text] [Related]
13. Radiotherapy and immunology.
Wang L; Lynch C; Pitroda SP; Piffkó A; Yang K; Huser AK; Liang HL; Weichselbaum RR
J Exp Med; 2024 Jul; 221(7):. PubMed ID: 38771260
[TBL] [Abstract] [Full Text] [Related]
14. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic colorectal cancer: KEYNOTE-651 Cohorts B and D.
Kim R; Tehfe M; Kavan P; Chaves J; Kortmansky JS; Chen EX; Lieu CH; Wong L; Fakih M; Spencer K; Zhao Q; Predoiu R; Li C; Leconte P; Adelberg D; Chiorean EG
Clin Colorectal Cancer; 2024 Jun; 23(2):118-127.e6. PubMed ID: 38762348
[TBL] [Abstract] [Full Text] [Related]
15. Upregulation of Immune checkpoint pd-l1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
Altves S; Guclu E; Yetisgin E; Bilecen K; Vural H
World J Microbiol Biotechnol; 2024 May; 40(7):204. PubMed ID: 38755413
[TBL] [Abstract] [Full Text] [Related]
16. Enhanced systemic antitumor efficacy of PD-1/pd-l1 blockade with immunological response induced by photodynamic therapy.
Sonokawa T; Fujiwara Y; Pan C; Komohara Y; Usuda J
Thorac Cancer; 2024 Jun; 15(18):1429-1436. PubMed ID: 38739102
[TBL] [Abstract] [Full Text] [Related]
17. Engineered nanomicelles targeting proliferation and angiogenesis inhibit tumour progression by impairing the synthesis of ceramide-1-phosphate.
Yadav P; Rana K; Chakraborty R; Khan A; Mehta D; Jain D; Aggarwal B; Jha SK; Dasgupta U; Bajaj A
Nanoscale; 2024 May; 16(21):10350-10365. PubMed ID: 38739006
[TBL] [Abstract] [Full Text] [Related]
18. Anti-Colon cancer Activity of Copper-Doped Folate Carbon Dots/MnO
Liu M; Xia Q; Wu X; Jin S; Xie Y; Yan R; Jin Y; Wang Z
Bioconjug Chem; 2024 Jun; 35(6):826-842. PubMed ID: 38722674
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma.
Hornstein NJ; Zeineddine MA; Gunes BB; Pellatt AJ; Knafl M; Zhu H; Willett AF; Yousef A; Liu S; Sun R; Futreal A; Woodman SE; Taggart MW; Overman MJ; Halperin DM; Raghav KP; Shen JP
Cancer Res Commun; 2024 May; 4(5):1363-1368. PubMed ID: 38709066
[TBL] [Abstract] [Full Text] [Related]
20. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract] [Full Text] [Related]
[Next]
